Detection of liver metastases: Comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations

Radiology

Volumn 225, Issue 3, 2002, Pages 766-772

  Del Frate, Chiara ^a   Bazzocchi, Massimo ^a   Mortele, Koenraad J ^b   Zuiani, Chiara ^a   Londero, Viviana ^a   Como, Giuseppe ^a   Zanardi, Romeo ^a   Ros, Pablo R ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Gadolinium; Iron; Liver neoplasms, metastases; Liver neoplasms, MR; Liver, MR; Magnetic resonance (MR), contrast media

Indexed keywords

GADOBENATE DIMEGLUMINE; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; BREATH HOLDING; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; EQUIPMENT; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PEROPERATIVE ECHOGRAPHY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO;

EID: 0036893501     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2253011854     Document Type: Article

References (23)

1. Baron R. Detection of liver neoplasms: Techniques and outcomes. Abdom Imaging 1994; 19:320-324.
2. Heiken JP, Weyman PJ, Lee JKT, et al. Detection of focal hepatic masses: Prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. Radiology 1989; 171:47-51.
3. Rummeny EJ, Wernecke K, Saini S, et al. Comparison between high-field-strength MR imaging and CT for screening of hepatic metastases: A receiver operating characteristic analysis. Radiology 1992; 182:879-886.
4. Wernecke K, Rummeny EJ, Bongartz G, et al. Detection of hepatic masses in patients with carcinoma: Comparative sensitivities of sonography, CT and MR imaging. AJR Am J Roentgenol 1991; 157:731-739.
5. Soyer P. CT during arterial portography. Eur Radiol 1996; 6:349-357.
6. Hahn PF, Saini S. Liver specific MR imaging contrast agents. Radiol Clin North Am 1998; 36:287-297.
7. Seneterre E, Taourel P, Bouvier Y, et al. Detection of hepatic metastases: Ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 1996; 200:785-792.
8. Denys A, Arrivé L, Servois V, et al. Hepatic tumors: Detection and characterization at 1T MR imaging enhanced with AMI-25. Radiology 1994; 193:665-669.
9. Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxides: A multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995; 196:481-488.
10. Hagspield KD, Neidl KFW, Eichenberger AC, et al. Detection of liver metastases: Comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 1995; 196:471-478.
11. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999; 6:282-291.
12. Bartolozzi C, Spinazzi A. MultiHance: Help or hype? J Comput Assist Tomogr 1999; 23(suppl 1):S151-S159.
13. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: Evaluation of the efficacy of gadobenate dimeglumine in MR imaging: A multicenter phase III clinical study. Radiology 2000; 215:727-736.
14. Pavone P, Patrizio G, Buoni C, et al. Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver. Radiology 1990; 176:61-64.
15. Hughes KS, Sugarbaker PH. Treatment of metastatic liver tumors. In Rosenberg SA, ed. Surgical Cure of Metastatic Cancer. Philadelphia, Pa: Lippincott, 1987.
16. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: Review of the first 5 years. AJR Am J Roentgenol 1990; 155:943-950.
17. Bellin MF, Zaim S, Auberton E, et al. Safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 1994; 193:657-663.
18. Duda SH, Laniado M, Kopp AF, et al. Superparamagnetic iron oxide: Detection of focal liver lesions at high-field-strength MR imaging. J Magn Reson Imaging 1994; 4:309-314.
19. Marchal G, Hecke PV, Demaerel P, et al. Detection of liver metastases with superparamagnetic iron oxide in 15 patients: Results of MR imaging at 1.5 T. AJR Am J Roentgenol 1989; 152:771-775.
20. Schwartz LH, Seltzer SE, Tempany CM, et al. Superparamagnetic iron oxide hepatic MR imaging: Efficacy and safety using conventional and fast spin-echo pulse sequences. J Magn Reson Imaging 1995; 5:566-570.
21. Taylor PM, Hawnaur JM, Hutchinson CE. Superparamagnetic iron oxide imaging of focal liver disease. Clin Radiol 1995; 50:215-219.
22. Cavagna F, Tirone P, Felder E, et al. Hepatobiliary contrast agents for MRI. In: Ferrucci JT, Stark DD, eds. Liver Imaging: Current Trends and New Techniques. Boston, Mass: Andover Medical, 1990; 384-393.
23. Shima W, Petersein J, Hahn PF, et al. Contrast enhanced MR imaging of the liver: Comparison between Gd-BOPTA and mangafodipir. J Magn Reson Imaging 1997; 7:417-423.